2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Ser/Thr Protease
  5. Ser/Thr Protease Inhibitor

Ser/Thr Protease Inhibitor

Ser/Thr Protease Inhibitors (146):

Cat. No. Product Name Effect Purity
  • HY-18234A
    Leupeptin hemisulfate
    		Inhibitor ≥98.0%
    Leupeptin hemisulfate is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin hemisulfate potently inhibits serine, cysteine and threonine proteases. Leupeptin hemisulfate inhibits Mpro (the main protease of SARS-CoV-2) and also has anti-inflammatory activity.
  • HY-12821
    AEBSF hydrochloride
    		Inhibitor 99.90%
    AEBSF hydrochloride is an irreversible inhibitor of serine proteases, such as chymotrypsin, kallikrein, plasmin, thrombin, and trypsin.
  • HY-13512
    Camostat mesylate
    		Inhibitor 99.93%
    Camostat mesylate (Camostat mesilate) is an orally active, synthetic serine protease inhibitor for chronic pancreatitis. Camostat mesylate, an inhibitor of TMPRSS2, shows antiviral activity against SARS-CoV-2. Camostat mesylate also inhibits the activity of prostasin, trypsin, and matriptase.
  • HY-132591A
    Inclisiran sodium
    		Inhibitor 98.10%
    Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran sodium can be used for hyperlipidemia and cardiovascular disease (CVD) research.
  • HY-126034
    3,4-Dichloroisocoumarin
    		Inhibitor 99.68%
    3,4-Dichloroisocoumarin is a potent serine-protease inhibitor that inhibits chymotrypsin-like activity.
  • HY-100626
    WNK463
    		Inhibitor 99.07%
    WNK463 is an orally bioavailable pan-With-No-Lysine (K) (WNK)-kinase inhibitor with IC50s of 5 nM, 1 nM, 6 nM, and 9 nM for WNK1, WNK2, WNK3, and WNK4, respectively.
  • HY-P0206
    Bradykinin
    		Inhibitor 99.86%
    Bradykinin is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions.
  • HY-B0190A
    Nafamostat mesylate
    		Inhibitor 99.85%
    Nafamostat mesylate (FUT-175), an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat mesylate has anticancer and antivirus effect. Nafamostat mesylate induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1). Nafamostat mesylate can be used in the development of the pathological thickening of the arterial wall3].
  • HY-132591
    Inclisiran
    		Inhibitor
    Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research.
  • HY-126388
    Trypsin Inhibitor, soybean
    		Inhibitor
    Trypsin Inhibitor, soybean is a potent and reversible inhibitor of trypsin.
  • HY-W018781
    Benzamidine hydrochloride
    		Inhibitor ≥98.0%
    Benzamidine hydrochloride is a trypsin-like serine proteases with Kis of 20, 21, 97, 110, 320 and 750 μM against Tryptase, Trypsin, uPA, Factor Xa, Thrombin and tPA, respectively.
  • HY-P9930
    Evolocumab
    		Inhibitor 98.40%
    Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation.
  • HY-120088A
    PF-06446846 hydrochloride
    		Inhibitor 99.85%
    PF-06446846 hydrochloride is an orally active and highly selective inhibitor of translation of Proprotein convertase subtilisin/kexin type 9 (PCSK9). PF-06446846 hydrochloride inhibits PCSK9 by inducing the ribosome to stall around codon 34.
  • HY-112094
    WNK-IN-11
    		Inhibitor 99.13%
    WNK-IN-11 is an allosteric With-No-Lysine (WNK) kinase inhibitor, with an IC50 of 4 nM for WNK1.
  • HY-12402
    SBC-115076
    		Inhibitor 99.54%
    SBC-115076 is a potent proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PCSK9 is a proprotein convertase, which plays a crucial role in LDL receptor metabolism.
  • HY-P99187
    Bococizumab
    		Inhibitor 99.9%
    Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia.
  • HY-P2276
    Pep2-8
    		Inhibitor 99.74%
    Pep2-8 is a PCSK9 inhibitor with a binding KD of 0.7 μM and an IC50 of 1.4 μM.
  • HY-16735
    Avoralstat
    		Inhibitor ≥98.0%
    Avoralstat (BCX4161), a potent and orally active plasma kallikrein (PKK) inhibitor, is used for hereditary angioedema research.
  • HY-111192
    IPR-803
    		Inhibitor ≥98.0%
    IPR-803 is a potent inhibitor of the uPAR•uPA protein-protein interaction (PPI). IPR-803 binds directly to uPAR with sub-micromolar affinity. IPR-803 displays anti-tumor activity.
  • HY-P9928
    Alirocumab
    		Inhibitor
    Alirocumab (REGN 727) is a human monoclonal antibody inhibitor of PCSK9. Alirocumab is a monoclonal antibody. Alirocumab has anti-inflammatory, antiangiogenic and antioxidant effects. Alirocumab can be used in the study of hypercholesterolemia.